FCE 28833A

Drug Profile

FCE 28833A

Latest Information Update: 05 Oct 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Class Amino acids; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action Kynurenine 3-monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders; Seizures

Most Recent Events

  • 05 Oct 1998 No-Development-Reported for Neurological disorders in Italy (Unknown route)
  • 05 Oct 1998 No-Development-Reported for Seizures in Italy (Unknown route)
  • 24 Jan 1997 Preclinical development for Neurological disorders in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top